International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 1 | Views: 94 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Research Paper | Medicine | India | Volume 12 Issue 3, March 2023

A Prospective Clinical Study to Evaluate the Role of Centchroman in the Treatment of Mastalgia and ANDI (Aberrations of Normal Development and Involution) of the Breast Surgery

Dr Ashita Kohli | Dr. Manisha Nigam [2] | Dr. Brijendra Nigam [2] | Dr. Surekha [5]

Abstract: Background: Benign breast disorders has been classified by the ANDI system (aberrations of normal development and involution of breast) and includes mastalgia, fibroadenoma among other disorders. Drugs used for these disorders are expensive with side effects and do not show any improvement. Ormeloxifene (Centchroman) is a selective estrogen modulator synthesized by the Central Drug Research Institute, Lucknow. It has been previously used in patients with mastalgia and fibroadenomaand has shown promising results. This study is being undertaken to understand the role of centchroman as an effective treatment for mastalgia and ANDI. Materials and Method: The present randomized control trial was conducted in the Department of Surgery, Rama Medical College Hospital & Research Centre, Mandhana, Kanpur, U. P which was conducted from January 2021 to September 2022. The study was conducted in two groupswith mastalgia and fibroadenoma. The trial was with 170 women of age 20 - 40 years with complaints of mastalgia (with or without nodularity) or with those with fibroadenoma <4cm. The collected data was analyzed by using SPSS (Statistical Package for Social Sciences) Version 15.0 Results: The trial of 170 women showed that married, multiparous women between ages 36 - 40 were affected the most by mastalgia and fibroadenoma. The mean VAS score for mastalgiaat 3 months after the use of Centchroman suggest that centrchroman is effective in reducing the pain of mastalgia. The size of lump before and after the use of Centchroman at 3 months in Fibroadenoma was reduced suggesting centchroman is effective in reducing size of lump. Conclusion: Centchroman is an effective drug for treatment of mastalgia and fibroadenoma.

Keywords: ANDI, Centchroman, Mastalgia, Fibroadenoma, Benign, Breast

Edition: Volume 12 Issue 3, March 2023,

Pages: 1570 - 1575

How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link

Verification Code will appear in 2 Seconds ... Wait